LEE WILLIS C, CEO, reported an open-market or private purchase at Emmaus Life Sciences, Inc. involving 94767.000000 shares for an estimated $5686.02. Reported holdings after the transaction were 590167.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
CEO
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.01 to $0.02, inclusive. The reporting person undertakes to provide to Emm…
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0109 to $0.011, inclusive.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.034 to $0.039, inclusive.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.044 to $0.051, inclusive.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.050 to $0.075, inclusive.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.046 to $0.05, inclusive.
0 other filings
0 recent txs